GSA Capital Partners’s Starling Oncology STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
JAIC
GSA Capital Partners's STLN Position: Q3 2026 in Review
GSA Capital Partners sold out of Starling Oncology (STLN) in Q3 2026, closing a stake of 98,727 shares — an estimated $536K sold.
GSA Capital Partners first reported a position in STLN in Q1 2025 and held it in 3 quarters. The position peaked at $536K in Q2 2026. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.
- GSA Capital Partners reported no remaining Starling Oncology position as of Q3 2026 after selling out during the quarter.
- GSA Capital Partners sold 98,727 Starling Oncology shares in Q3 2026, an estimated $536K.
- GSA Capital Partners first reported a position in Starling Oncology in Q1 2025 and held it in 3 quarters.
- GSA Capital Partners's Starling Oncology position peaked at $536K in Q2 2026.
- 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.